ImmunityBio, Inc. (Nasdaq: IBRX), the California-based commercial-stage immunotherapy developer, announced on October 14, 2026, that the United States Food and Drug Administration has expanded the approved indication for ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin to include adults with BCG-unresponsive high-grade papillary-only non-muscle-invasive bladder cancer. The decision broadens the medicine’s previous April 2024 authorization, which covered patients with carcinoma in situ, with or without accompanying papillary tumors.
The revised indication allows ANKTIVA plus BCG to be used across the FDA-recognized BCG-unresponsive non-muscle-invasive bladder cancer population, including eligible patients whose disease consists of high-grade papillary tumors without carcinoma in situ. The FDA describes this as the first specific United States approval of a treatment for the papillary-only BCG-unresponsive population. The expansion creates another bladder-preserving treatment option for selected patients facing recurrence or progression after standard intravesical immunotherapy.
The most consequential feature of the approval is its evidentiary basis. Rather than relying on a newly completed randomized efficacy trial in papillary-only disease, the FDA extrapolated from the earlier QUILT-3.032 study in patients with carcinoma in situ and reviewed clinical and biological evidence supporting similarities between the two forms of aggressive bladder cancer. In the original FDA efficacy population of 77 patients, 62% achieved a complete response, with 58% of responders maintaining that response for at least 12 months.
The decision also arrives during a period of commercial expansion for ImmunityBio. ANKTIVA generated $50.7 million in net product revenue during the second quarter of 2026, increasing 92% from the previous year. The broader indication could expand the population eligible for treatment, although the company has not disclosed a reliable forecast for incremental prescriptions, revenue or the proportion of papillary-only patients who will receive the therapy.
Why does FDA approval for papillary-only non-muscle-invasive bladder cancer matter?
Non-muscle-invasive bladder cancer refers to tumors that remain within the bladder lining or underlying connective tissue without invading the muscular wall. It represents a substantial majority of newly diagnosed bladder cancers and includes several different pathological presentations. Two important forms are carcinoma in situ, a flat high-grade lesion, and papillary tumors, which grow outward from the bladder lining.
Papillary tumors may be classified as low-grade or high-grade, and their clinical risks differ substantially. High-grade papillary disease is more likely to recur or progress than lower-grade disease and can require intensive treatment and surveillance. The new FDA decision specifically addresses BCG-unresponsive high-grade papillary-only disease, not every patient diagnosed with a papillary bladder tumor.
Patients with high-risk non-muscle-invasive bladder cancer are commonly treated initially with transurethral resection of visible tumors followed by intravesical BCG. BCG stimulates immune activity within the bladder and can reduce recurrence or progression in appropriately selected patients. However, some tumors persist or return despite adequate treatment.
For patients whose disease becomes BCG-unresponsive, radical cystectomy has historically been a major treatment consideration because of the risk of progression to muscle-invasive or metastatic cancer. Although surgery can offer important disease control, removal of the bladder involves substantial physical and quality-of-life consequences. Effective bladder-preserving treatments are therefore clinically valuable, provided they do not delay necessary surgery in patients whose cancer is progressing.
Until the latest decision, ANKTIVA’s United States authorization was restricted to carcinoma in situ with or without papillary disease. The expanded label closes that regulatory distinction for eligible patients with papillary-only disease, allowing physicians to consider ANKTIVA plus BCG without the previous limitation requiring the presence of CIS.
How did the FDA justify approval without a new pivotal efficacy study in papillary-only disease?
The FDA based its decision on evidence supporting the original ANKTIVA approval and the scientific relationship between the disease populations. The agency concluded that high-grade papillary tumors and carcinoma in situ have sufficiently overlapping clinical and nonclinical characteristics to support extrapolating efficacy evidence from one population to the other. This represents an important regulatory decision about how existing clinical evidence can be applied to closely related cancer presentations.
Although the two tumor types differ in appearance, both represent aggressive urothelial carcinoma and may coexist within the same bladder. Their microscopic features can sometimes be difficult to distinguish, and both carry substantial risks of recurrence and progression after BCG failure. The FDA considered these shared features relevant when determining whether a separate definitive efficacy demonstration was necessary for papillary-only disease.
The agency’s approval information identifies the original QUILT-3.032 carcinoma in situ cohort as the central efficacy foundation. That study demonstrated activity in patients with CIS, including some with associated papillary tumors, but it did not produce the same kind of prospective controlled evidence specifically comparing ANKTIVA with standard treatment in papillary-only disease.
ImmunityBio separately investigated papillary-only disease in another cohort of QUILT-3.032. The company previously reported a 12-month disease-free survival rate of 58.2% among 80 patients in that cohort, with a 95% confidence interval of 46.6% to 68.2%. However, those findings came from a nonrandomized study and should not be presented as the randomized efficacy result establishing the new indication.
The FDA’s announcement is particularly notable because it explicitly describes a broader approach to applying evidence across related pathological forms of bladder cancer. The agency is also working toward finalizing guidance addressing drug development in BCG-unresponsive non-muscle-invasive bladder cancer, including the circumstances in which extrapolation from CIS studies may support treatment approval for papillary-only disease.
This approach may influence future oncology development programmes, but it should not be interpreted as a general relaxation of efficacy requirements. The scientific justification depends on the relationship between the particular disease populations and the totality of evidence available for the treatment under review.
What did the original QUILT-3.032 study establish about ANKTIVA’s efficacy?
The FDA’s original approval was based on Cohort A of QUILT-3.032, a single-arm, multicenter study involving 77 patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer containing carcinoma in situ, with or without Ta or T1 papillary tumors. Patients received ANKTIVA together with BCG through intravesical instillation. Treatment included an induction phase followed by maintenance according to the protocol.
The study’s primary efficacy assessment was complete response, determined through evaluation including cystoscopy, urine cytology and biopsy. The reported complete response rate was 62%, with a 95% confidence interval of 51% to 73%. This indicates that a substantial proportion of participants had no detectable high-grade disease under the study’s response criteria following treatment.
Duration of response provided additional information about the persistence of benefit. Among patients achieving complete response, 58% maintained that response for at least 12 months and 40% for at least 24 months. These findings supported evidence that the treatment could produce sustained disease control in some patients.
However, complete response in CIS-associated disease and disease-free survival after removal of papillary tumors are not interchangeable endpoints. Papillary lesions are commonly resected before subsequent intravesical therapy, changing how recurrence and treatment benefit are assessed. This is one reason the new approval’s reliance on scientific extrapolation must be clearly distinguished from a direct response-rate finding in papillary-only patients.
The original study was also nonrandomized, meaning it did not directly compare ANKTIVA plus BCG against a concurrent randomized control group. The findings supported regulatory approval in a setting with substantial unmet need, but they cannot establish superiority over every available bladder-preserving treatment.
How does ANKTIVA’s IL-15 mechanism differ from BCG alone?
ANKTIVA is an interleukin-15 receptor agonist complex designed to stimulate immune cells involved in recognizing and attacking abnormal cells. It contains a modified IL-15 component combined with an IL-15 receptor alpha-related structure and an immunoglobulin-based component. The design is intended to enhance biological signaling associated with natural killer cells and certain T-cell populations.
Interleukin-15 contributes to the development, maintenance and activation of immune cells, including cytotoxic CD8-positive T cells and natural killer cells. By stimulating these pathways, ANKTIVA aims to strengthen the immune response against malignant cells within the bladder. Its role is therefore complementary to BCG, which also activates local immune responses but through a different biological mechanism.
The combination is administered directly into the bladder rather than through routine intravenous infusion or subcutaneous injection. This intravesical approach places the treatment in contact with the bladder lining and is consistent with the established method used for BCG immunotherapy. The objective is to generate antitumor immune activity within the affected tissue.
The company has described the potential for ANKTIVA to support immune-cell memory and sustained tumor control. The clinical response durations observed in QUILT-3.032 are consistent with meaningful activity in some patients, but they do not independently establish the precise immune mechanism responsible for every response. Laboratory observations and clinical outcomes remain distinct types of evidence.
ANKTIVA is not an approved replacement for BCG in the newly expanded indication. Its FDA authorization specifies treatment in combination with BCG, meaning product availability and treatment planning depend on the ability to administer both components appropriately.
What are the approved ANKTIVA dose and treatment schedule?
The FDA recommends ANKTIVA at a dose of 400 micrograms administered intravesically together with BCG once weekly for six weeks during induction. A second induction course may be used in certain patients with residual qualifying disease at the three-month assessment. The treatment schedule therefore requires repeated catheter-based administration and ongoing disease monitoring.
Maintenance treatment may be administered once weekly for three weeks at months 4, 7, 10, 13 and 19, representing up to 15 additional doses during that phase. For eligible patients without high-grade disease at month 25 or later, further maintenance courses may be given at months 25, 31 and 37. The maximum treatment duration is 37 months under the approved schedule.
The treatment should be discontinued when disease persists after the permitted second induction, when recurrence or progression occurs, or when adverse effects become unacceptable. This requirement is particularly important because delaying effective management of progressive bladder cancer can have serious consequences.
Regular surveillance remains essential. Patients with non-muscle-invasive bladder cancer may require cystoscopy, urine testing and biopsy according to their clinical circumstances. An apparent initial response does not eliminate the possibility of subsequent recurrence, making follow-up integral to any bladder-preserving strategy.
The new indication does not remove these requirements or establish a simplified treatment schedule for papillary-only disease. Physicians must use the approved prescribing information and evaluate whether continued intravesical therapy remains appropriate.
What safety risks remain after the expanded ANKTIVA approval?
The combination’s safety profile includes adverse effects associated with local bladder administration and immune activation. Common reactions and laboratory abnormalities reported in the approved clinical programme included increased creatinine, painful urination, blood in the urine, urinary frequency, urinary urgency, urinary tract infections, increased potassium, musculoskeletal pain, chills and fever. Many events were mild or moderate, but clinically important complications require monitoring.
The most consequential warning concerns the danger of delaying cystectomy when cancer is not adequately controlled. The FDA warns that postponing surgery can allow progression to muscle-invasive or metastatic bladder cancer, which can be fatal. This warning is particularly relevant because bladder preservation is a central treatment objective for many patients.
The new indication should therefore not be interpreted as evidence that all patients can safely avoid bladder removal. Some individuals will still require surgery depending on disease persistence, recurrence, progression, risk factors and their overall clinical circumstances. Appropriate patient counseling and surveillance remain essential.
The expanded approval also does not establish that ANKTIVA has a more favorable safety profile than every other available treatment. No new randomized safety comparison was announced in conjunction with the October decision. The evidence supports an authorized treatment option within the defined population rather than a universal safety advantage.
How could the label expansion affect ImmunityBio’s commercial growth?
ImmunityBio’s latest reported financial results showed accelerating ANKTIVA sales before the expanded indication was granted. Net product revenue reached $50.7 million during the second quarter of 2026, an increase of 92% from the same period in 2025 and 15% from the preceding quarter. First-half product revenue totaled $94.8 million, compared with substantially lower sales a year earlier.
The company also reported approximately $357.4 million in cash, cash equivalents and marketable securities at June 30, 2026. These resources provide financial support for commercialization and ongoing clinical development, although future spending requirements remain substantial. The latest regulatory decision may increase demand, but no revised financial guidance directly attributable to the expanded label was disclosed.
ImmunityBio has emphasized that papillary disease represents the majority of non-muscle-invasive bladder cancer presentations. However, the commonly cited figure of approximately 85% refers to patients presenting with papillary disease across the broader NMIBC population. It should not be interpreted as meaning that 85% of all newly diagnosed patients automatically qualify for ANKTIVA.
Eligibility requires the relevant high-grade BCG-unresponsive disease setting, and the actual commercially addressable population will be substantially more specific. Additional factors include patient fitness, availability of BCG, physician recommendations, insurance coverage and willingness to undergo a prolonged intravesical treatment programme.
The company has also been working to support BCG supply through an agreement with Japan BCG Laboratory involving the Tokyo-172 strain. Supply availability is important because ANKTIVA’s approved regimen requires BCG coadministration. Expansion of treatment eligibility could increase the operational importance of reliable supply arrangements.
What does the earlier-than-expected FDA decision mean for ImmunityBio’s regulatory strategy?
The FDA accepted ImmunityBio’s supplemental Biologics License Application for papillary-only disease in May 2026 and initially assigned a target action date of January 6, 2027. The October 14 approval therefore arrived ahead of that previously announced deadline. It removes a near-term regulatory uncertainty concerning the requested expansion.
The decision also follows an earlier international authorization with a broad indication. In July 2026, the United Arab Emirates granted marketing authorization covering ANKTIVA’s intravesical use across BCG-unresponsive non-muscle-invasive bladder cancer, alongside a separate authorization for a different formulation and combination treatment in metastatic non-small cell lung cancer. These approvals involve distinct populations, routes of administration and evidence requirements.
The FDA’s newly expanded bladder cancer authorization should not be interpreted as approval of ANKTIVA for metastatic lung cancer in the United States. Nor does it establish that every immunotherapy combination under investigation by ImmunityBio has demonstrated efficacy. Each proposed indication remains subject to its own regulatory framework.
The company’s broader research includes additional bladder cancer settings and other malignancies. The October approval may strengthen its commercial foundation, but subsequent label extensions will still depend on sufficient evidence and regulatory review.
For the treatment landscape, the decision illustrates how regulators may use established efficacy evidence when closely related disease presentations share relevant biological and clinical characteristics. That approach could influence future drug development, although its application will need to be justified separately in other programmes.
The FDA’s expansion of ANKTIVA plus BCG marks a meaningful change for adults with high-grade papillary-only bladder cancer that has become unresponsive to standard BCG treatment. It provides an FDA-approved option beyond the original CIS-associated indication and extends the use of a medicine already generating substantial commercial revenue.
The central clinical limitation remains the distinction between the original efficacy findings and the newly included population. The 62% complete response rate belongs to patients with CIS-associated disease, while the papillary-only approval relies on scientific extrapolation supported by additional available evidence. Real-world outcomes, treatment persistence and careful surveillance will now help determine how the broader indication affects bladder preservation in routine practice.
